Amylin Pharma (AMLN) Reports Q4 GAAP Loss of $3.15/Share
Get Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Research and development: 51.24M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Research and development: 51.24M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q4 GAAP loss of $3.15, which does not compare to the analyst estimate of ($0.08). The company posted a loss per share of 13 cents during the same quarter last year. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $163.64 million.
For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.
For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Union Pacific (UNP) Tops Q1 EPS by 18c
- Equinor ASA (EQNR) Tops Q1 EPS by 22c, misses on revenue
- Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!